AI Article Synopsis
- The SPOT-MAS assay detects five common cancers in Vietnam by analyzing circulating tumor DNA in blood samples.
- It was validated in the K-DETEK clinical trial involving 2,795 participants across 14 sites, showing a 60% positive predictive value and 83.3% accuracy in identifying tumor locations.
- The study suggests that SPOT-MAS can be used as a complementary method for early cancer detection, potentially leading to timely treatment opportunities.
Article Abstract
The SPOT-MAS assay "Screening for the Presence Of Tumor by Methylation And Size" detects the five most common cancers in Vietnam by evaluating circulating tumor DNA in the blood. Here, we validated its performance in a prospective multi-center clinical trial, K-DETEK. Our analysis of 2795 participants from 14 sites across Vietnam demonstrates its ability to detect cancers in asymptomatic individuals with a positive predictive value of 60%, with 83.3% accuracy in detecting tumor location. We present a case report to support further using SPOT-MAS as a complementary method to achieve early cancer detection and provide the opportunity for early treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/07357907.2023.2173773 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!